Early Treatment with Poly(ADP-Ribose) Polymerase-1 Inhibitor (JPI-289) Reduces Infarct Volume and Improves Long-Term Behavior in an Animal Model of Ischemic Stroke

Reconsidering Neuroprotection in the Reperfusion Era

(2017) Sean I. Savitz et al.   STROKE

Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research

(2017) Cesar Reis et al.   Biomed Research International

Strategies to Extend Thrombolytic Time Window for Ischemic Stroke Treatment: An Unmet Clinical Need

(2017) Ike dela Peña et al.   Journal of Stroke

Early Activation of Phosphatidylinositol 3-Kinase after Ischemic Stroke Reduces Infarct Volume and Improves Long-Term Behavior

(2016) Young Seo Kim et al.   MOLECULAR NEUROBIOLOGY

Neuroprotective Effects of Poly(ADP-ribose)polymerase Inhibitor Olaparib in Transient Cerebral Ischemia

(2016) Fei Teng et al.   NEUROCHEMICAL RESEARCH

Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors

(2015) Haiping Yao et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Poly(ADP-ribose) Polymerase-1 Inhibition in Brain Endothelium Protects the Blood—Brain Barrier under Physiologic and Neuroinflammatory Conditions

(2014) Slava Rom et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Discovery and Structure–Activity Relationship of Novel 2,3-Dihydrobenzofuran-7-carboxamide and 2,3-Dihydrobenzofuran-3(2H)-one-7-carboxamide Derivatives as Poly(ADP-ribose)polymerase-1 Inhibitors

(2014) Maulik R. Patel et al.   JOURNAL OF MEDICINAL CHEMISTRY

Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities

(2013) Amos A Fatokun et al.   BRITISH JOURNAL OF PHARMACOLOGY

Regulatory T Cell in Stroke: A New Paradigm for Immune Regulation

(2013) Sheng Chen et al.   Clinical & Developmental Immunology

Prevention of rt-PA induced blood–brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice

(2013) Fei Teng et al.   EXPERIMENTAL NEUROLOGY

Beyond DNA repair, the immunological role of PARP-1 and its siblings

(2013) Maria Manuela Rosado et al.   IMMUNOLOGY

Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice

(2012) Marianne Haddad et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis

(2012) Joanna M Wardlaw et al.   LANCET

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Christopher J L Murray et al.   LANCET

Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator

(2012) Federica Laudisi et al.   Endocrine Metabolic & Immune Disorders-Drug Targets

Neuroprotective effects of a novel water-soluble poly(ADP-ribose) polymerase-1 inhibitor, MP-124, in in vitro and in vivo models of cerebral ischemia

(2011) Yasuhiro Egi et al.   BRAIN RESEARCH

Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase

(2011) F Moroni et al.   BRITISH JOURNAL OF PHARMACOLOGY

Sex Differences in the Response to Poly(ADP-ribose) Polymerase-1 Deletion and Caspase Inhibition After Stroke

(2011) Fudong Liu et al.   STROKE

Poly(ADP-Ribose) Metabolism in Brain and Its Role in Ischemia Pathology

(2010) Robert Piotr Strosznajder et al.   MOLECULAR NEUROBIOLOGY

Sex differences in the response to activation of the poly (ADP-ribose) polymerase pathway after experimental stroke

(2009) Mike Yuan et al.   EXPERIMENTAL NEUROLOGY

Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations

(2009) Marc Fisher et al.   STROKE

Inhibition of GSK-3 reduces infarct volume and improves neurobehavioral functions

(2008) Seong-Ho Koh et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Post-ischemic brain damage: targeting PARP-1 within the ischemic neurovascular units as a realistic avenue to stroke treatment

(2008) Flavio Moroni et al.   FEBS Journal

Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage

(2007) F MORONI   CURRENT OPINION IN PHARMACOLOGY